Navigation Links
Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook
Date:2/8/2011

hat its business model delivers results; the company's expectation that growth in top-line revenue will be driven almost exclusively by increasing adoption of its breast cancer test; the company's ability to accelerate the development of a test for prostate cancer and the potential timing of the launch of a new test for prostate cancer; the  success or results of clinical trials and the timing of such activities; the applicability of clinical study results to actual outcomes; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; our success retaining current contracts or levels of reimbursement coverage for our tests; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to successfully commercialize our products outside of the US; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health l
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... new analysis of Centers for Medicare and Medicaid Services, ... 81 percent of seniors chose lower-cost preferred pharmacy plans ... pharmacies. The findings were released by Drug Channels ... foundation of Medicare Part D," said Pharmaceutical Care Management ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Oct. 7 DiFUSION Technologies is a medical ... of its proprietary CleanFUZE™ antimicrobial technology for orthopedic ... Interbody products for spinal surgery. "Post-operative ... the further proliferation of drug resistant bacteria, preventing ...
... Community Pharmacists Association (NCPA) has announced its current ... and Trade Exposition scheduled for October 23-27, 2010 ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100106/DC33253LOGO ) (Logo:   ... Exposition is the most powerful and productive trade ...
Cached Medicine Technology:DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial 2DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial 3NCPA Announces Exhibit Hall Activities for 2010 NCPA Annual Convention and Trade Exposition 2
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that focuses ... representation client review requests for slip and fall accidents in ... the number of slip and fall related accidents that happen ... that said, a large number of injury victims are requesting ... Hastings and Hastings is a personal injury firm in Arizona ...
(Date:1/22/2015)... 23, 2015 LunaDress, with its top dressmaking ... industry. Now, the business is showing its latest designs of ... , According to the company’s CEO, all the fresh new ... with big discounts, up to 80% off. All the clothes ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... treatment plan used to prevent potentially dangerous blood clots ... immobilized by acute medical illness, doctors have found in ... or older, and patients strictly confined to 24-hour bed ... thinner significantly reduced the chances of blood clots while ...
... Gardner HealthDay Reporter , TUESDAY, July 6 (HealthDay ... blood pressure levels in type 2 diabetics who also have ... and coronary artery disease did not have fewer strokes or ... their blood pressure was maintained under 130 mm Hg, compared ...
... in French . Montreal, July 6, ... Research in Immunology and Cancer (IRIC) of the University of ... (hematopoietic) stem cells. The study led by IRIC Chief Executive ... control the production of hematopoietic stem cells. Published in the ...
... than one species of bacteria could be more persistent ... the other, encouraging it to bolster its defenses. ... curing these infections. Researchers from Wake Forest University ... mBio , the online open-access journal of the American ...
... ... expansion into Brooklyn, New York through a merger with Otolaryngology Associates. , ... Tarrytown, NY (Vocus) July 6, 2010 -- ... into Brooklyn, New York through a merger with Otolaryngology Associates. This will result in a ...
... Los Angeles and childhood cancer patients will together take part in ... their hands in fingerpaint and apply colorful handprints to a white ... handprints from all over the country, is the symbol of Hyundai ... cure rate means that in the general population of young adults, ...
Cached Medicine News:Health News:Extended use of anti-clotting drug helps some bedridden patients 2Health News:Extended use of anti-clotting drug helps some bedridden patients 3Health News:Tight Blood Pressure Control Doesn't Help All Diabetics: Study 2Health News:Researchers identify factors behind blood-making stem cells 2Health News:Bacterial communication encourages chronic, resistant ear infections 2Health News:ENT and Allergy Associates Adds Two Offices in Brooklyn, NY -- Practice Grows to 110 Physicians, 2Health News:ENT and Allergy Associates Adds Two Offices in Brooklyn, NY -- Practice Grows to 110 Physicians, 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: